Sartorius acquires majority stake in CellGenix

By The Science Advisory Board staff writers

Life science company Sartorius has acquired a 51% stake in reagent manufacturer CellGenix through its subsidiary Sartorius Stedim Biotech.

The stake is worth 100 million euros ($118 million U.S.), Sartorius said. It plans to purchase CellGenix's remaining shares at the beginning of 2023 and 2026.

CellGenix is based in Freiburg, Germany, but also has a sales office in Boston. It produces and markets cell culture components like growth factors, cytokines, and media for cell and gene therapy purposes and in 2020 generated sales of more than 20 million euros ($23.6 million).

Sartorius plans to expand the company's Freiburg site for manufacturing purposes, it said.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?